The efficiency result came from a randomized diagnostic-endoscopy population, with follow-up ending at discharge.
Of 133 randomized participants, 132 underwent sedated upper endoscopy, sixty-six per group. Total procedure-related time averaged 30.3 minutes with remimazolam versus 48.5 minutes with midazolam. Induction, sedation, recovery and discharge intervals were shorter. Overall adverse-event frequency did not clearly differ, and patient satisfaction relative to previous sedation experience favored remimazolam.
The study included ASA I and II patients having diagnostic procedures. It does not establish the same workflow difference in more medically complex patients or therapeutic endoscopy. Follow-up ended at discharge, limiting conclusions about delayed effects. Numerically fewer specific adverse events do not automatically establish a statistically demonstrated safety difference.
For an operational or clinical review, define which components are included in total time and compare the local discharge process. Patient satisfaction measured against an earlier experience may involve factors beyond the sedative. This trial supports a defined workflow comparison, while leaving postdischarge performance and rare complications unresolved. It cannot establish that a person’s judgment or memory had fully recovered merely because a discharge score was reached.
Source: PMC12811999, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Remimazolam Endoscopy Induction Success Was Different From Completion Success.